{"id":6577,"date":"2025-04-17T03:53:41","date_gmt":"2025-04-17T07:53:41","guid":{"rendered":"https:\/\/www.packagingindustrynews.com\/?p=6577"},"modified":"2025-04-17T03:53:41","modified_gmt":"2025-04-17T07:53:41","slug":"ritedose-to-double-single-vial-packaging-capabilities-with-seventh-syntegon-line","status":"publish","type":"post","link":"https:\/\/www.packagingindustrynews.com\/?p=6577","title":{"rendered":"Ritedose to double single-vial packaging capabilities with seventh Syntegon line\u00a0"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \n <\/picture>
The additional packaging line will play a key role in the manufacturing of Ohtuvayre. Credit: Matveev Aleksandr \/ Shutterstock.<\/figcaption><\/figure>\n<\/p><\/div>\n

Ritedose, a sterile contract manufacturing organisation, is expanding its manufacturing facility with a seventh Syntegon-branded packaging line.<\/p>\n

This expansion will effectively double the company\u2019s capacity to produce individually wrapped vial medications.<\/p>\n

Currently, the automated system is undergoing site acceptance testing at the Ritedose facility, with the new packaging line expected to start operations in the coming months.<\/p>\n

The new Syntegon packaging system will increase the company\u2019s annual processing range by between 160 and 170 million vials.<\/p>\n

This expansion not only enhances efficiency and flexibility but also enables Ritedose to offer a wider array of packaging options to meet the diverse requirements of its customers, the company said.<\/p>\n

The additional packaging line will play a crucial role in the manufacturing of Ohtuvayre, a novel chronic obstructive pulmonary disease\u00a0treatment from Verona Pharma.<\/p>\n

Ritedose\u2019s partnership with Verona, announced in September 2024, positions the company as a key player in the production of this medication. <\/p>\n

For more than two decades, Ritedose has partnered with Syntegon Technology for its processing and packaging needs.<\/p>\n

The latest packaging line is tailored for the automated secondary packaging of pharmaceutical and consumer goods, emphasising Ritedose\u2019s efforts towards patient safety and quality.<\/p>\n

The line\u2019s design focuses on maximising output and significantly reducing waste.<\/p>\n

Ritedose president and CEO\u00a0Jody Chastain\u00a0said: \u201cAt Ritedose, we make significant investments to support our expanding manufacturing efforts. This summer we expanded our sterile blow-fill-seal (BFS) capabilities by an additional 180-million-unit dose capacity for ophthalmic and respiratory medications.<\/p>\n

\u201cThese investments underscore our commitment to meeting the demands for high-quality, sterile unit dose solutions. Our seventh Syntegon packaging line will greatly enhance our ability to serve Verona Pharma and future clients.\u201d<\/p>\n

Earlier this month, Syntegon launched its latest MLD Advanced<\/a> filling machine, tailored for ready-to-use nested syringes.<\/p>\n

<\/p>\n

<\/p>\n

\n